Pegvaliase
Pegvaliase (trade name Palynziq) is a medication for the treatment of the genetic disease phenylketonuria.[1] Chemically, it is a pegylated derivative of the enzyme phenylalanine ammonia-lyase that metabolizes phenylalanine to reduce its blood levels.[2]
Clinical data | |
---|---|
Trade names | Palynziq |
Other names | Pegvaliase-pqpz; PEG-PAL; RAvPAL-PEG |
Routes of administration | Subcutaneous injection |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
3D model (JSmol) | |
| |
|
It was approved by the Food and Drug Administration for use in the United States in 2018.[1]
References
- "FDA approves a new treatment for PKU, a rare and serious genetic disease". Food and Drug Administration. May 24, 2018.
- "Palynziq". BioMarin Pharmaceutica.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.